---
title: "Incyte Corp. Stock Outperforms Competitors On Strong Trading Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285998147.md"
description: "Incyte Corp. (INCY) shares rose 1.79% to $100.32 on a strong trading day, outperforming competitors like Alnylam Pharmaceuticals, Bio-Techne, and BioMarin, which saw declines. The S&P 500 and Dow Jones both increased by 0.19%. Incyte's stock is currently 10.66% below its 52-week high of $112.29 reached on January 7th, with trading volume at 1.7 million, surpassing its 50-day average of 1.5 million."
datetime: "2026-05-11T21:08:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285998147.md)
  - [en](https://longbridge.com/en/news/285998147.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285998147.md)
---

# Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Incyte Corp. (INCY) rallied 1.79% to $100.32 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.19% to 7,412.84 and the Dow Jones Industrial Average rising 0.19% to 49,704.47.

This was the stock's second consecutive day of gains.

Incyte Corp. closed 10.66% short of its 52-week high of $112.29, which the company achieved on January 7th.

The stock outperformed some of its competitors Monday, as Alnylam Pharmaceuticals Inc. (ALNY) fell 3.46% to $284.84, Bio-Techne Corp. (TECH) fell 1.94% to $47.42, and BioMarin Pharmaceutical Inc. (BMRN) fell 2.74% to $52.58.

Trading volume (1.7 M) eclipsed its 50-day average volume of 1.5 M.

Data source: Dow Jones Market Data, FactSet. Data compiled May 11, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-11-26 1708ET

### Related Stocks

- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [TECH.US](https://longbridge.com/en/quote/TECH.US.md)
- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Incyte And Genesis Expand Molecular Ai Collaboration To Accelerate Drug Discovery](https://longbridge.com/en/news/287067847.md)
- [Incyte expands Genesis Molecular AI collaboration, pays USD 120 million upfront](https://longbridge.com/en/news/287060301.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)